Big Take: Who's Footing the Bill for Trump's Tariffs?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Hyperscience Recognized on the 2025 Inc. 5000 List of Fastest-Growing Private Companies in America
Groundbreaking AI and ML models and explosive demand for its Intelligent Document Processing platform across public and private sectors propel the company forward NEW YORK, August 12, 2025--(BUSINESS WIRE)--Hyperscience, a market leader in hyperautomation and a provider of enterprise AI infrastructure software, today announced its inclusion on the prestigious 2025 Inc. 5000 list of America's fastest-growing private companies. The company's proven success in delivering operational efficiencies across numerous verticals has earned it a spot on the list for the first time. This placement comes on the heels of a breakout year marked by the release of the company's Optical Reasoning and Cognition Agent (ORCA), its next-generation Vision-Language Model (VLM), and rapid adoption of its platform across government agencies, global enterprises, and regulated industries. "Being recognized on the Inc. 5000 list for the first time reflects the years of hard work and commitment of our teams, and is a testament to our achievements in leading the charge for intelligent automation," said Andrew Joiner, CEO of Hyperscience. "At Hyperscience, we're not just building AI, we're reshaping how the world works with information. This placement reinforces our mission to deliver AI that understands, empowers, and accelerates outcomes for organizations everywhere." Hyperscience transforms organizations everywhere with a turnkey AI platform that accelerates the processing of documents and forms that flow through an enterprise's back office. Designed with a "human-in-the-loop" approach, this platform leverages the strengths of both humans and machines. Hyperscience comprehensively manages data from input to extraction, orchestrating end-to-end processes. With industry-leading accuracy (99.5 percent) and automation (98 percent), Hyperscience automates tedious tasks, enabling workforces to spend their time on higher-level projects. The Inc. 5000 list, compiled annually by Inc. magazine, ranks the 5000 fastest-growing private companies in the United States based on revenue growth over the past three years. Making the Inc. 5000 is a significant achievement that places Hyperscience among the most dynamic and successful businesses in the country. For the full list, company profiles, and a searchable database by industry and location, visit: About Hyperscience Hyperscience is a market leader in hyperautomation and a provider of enterprise AI infrastructure software. The Hyperscience Hypercell platform unlocks the value of an organization's back office data through the automation of end-to-end processes, and transforms complex documents into LLM and RAG-ready data to power new enterprise GenAI experiences. This enables organizations to transform manual, siloed processes into a strategic advantage, resulting in a faster path to decisions, actions, and revenue; positive and engaging customer, public, and patient experiences; and dramatic increases in productivity. Leading organizations across the globe rely on Hyperscience to drive their hyperautomation initiatives, including American Express, Charles Schwab, HM Revenue and Customs, Mars, Stryker, The United States Social Security Administration, and The United States Department of Veterans Affairs. The company is funded by top tier investors including Bessemer Venture Partners, Battery, FirstMark, Stripes, and Tiger Global. View source version on Contacts Media Jyotsna (415) 917-7411 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
I'm a 22-Year-Old With Over $30K in My Bank Account: 7 Pieces of Advice From a Financial Advisor
According to a study by Amerisleep, 49% of Americans admitted to losing sleep over financial stress in 2025. The survey also noted that 56% of Americans have lost sleep because they fear that they won't be able to pay their bills. While stressing about money isn't rare, it's important to start taking your finances seriously from an early age so that you can get a head start. See Next: For You: A thread on Reddit sparked conversation because a 22-year-old electrician asked for advice on what they should do with their savings. This user shared a screenshot indicating that they had $22,000 saved in emergency funds and $10,000 in savings. We spoke with a financial advisor and expert to gather tips for this Reddit user and any other young person in this situation. Reserve Money Needed for Living Expenses 'The first step is to carve out one month of expenses to leave in your primary bank for day-to-day expenses,' said Hanna Kaufman, certified financial planner (CFP) and financial expert from Betterment. You want to start by leaving enough money in your primary bank account to cover bills for one month at a time. You always want your checking account to have enough to handle any payments so that you don't risk money that you need in the short term by investing it. This means that the first step is to take stock of your monthly bills so that you know how much you have going out. You can also look into reducing some fixed expenses by cutting a subscription or renegotiating the current rate so that you can continue to build your savings. Either way, being organized with your monthly income and expenses is helpful. Trending Now: Create a Clear Plan for Emergency Savings While having $22,000 saved up for an emergency is helpful, it's worth mentioning that you want the bulk of your savings to be used towards growing your net worth. 'Move the excess into a high-yield savings account (HYSA), where it can earn 4% to 4.25% APY. That's hundreds of dollars a year in passive income with zero risk,' Kaufman added. Kaufman said this person should keep a minimum of three months of expenses in a separate emergency fund. She stressed that an emergency fund is your financial seatbelt because it's essential when you need it. Kaufman noted that with your cash needs covered, the next priority is tackling debt and building long-term wealth. Pay Down Any Debt Kaufman emphasized the importance of managing your debt wisely. While it's unknown if this person has any debt, it's crucial that you make on-time minimum payments to protect your credit and avoid penalties. This person could get aggressive with making their debt payments if they have any high-interest loans at the moment. Start Investing To Ensure Your Money Works for You 'Parking $30,000 in a low-interest account is like planting seeds and never watering them,' Kaufman explained. 'You're sitting on potential, not progress.' Financial experts universally agree that investing your funds is crucial to ensure you benefit from compound interest. You want your money working for you instead of sitting in an account that earns very little interest. 'Investors need to begin compounding early and let that compounding work its patient magic over decades,' said Robert Johnson, Ph.D., chartered financial analyst (CFA), chartered alternative investment analyst (CAIA) and professor of finance at Creighton University. 'The longer your time horizon, the more you let compounding work for you.' Since this person is only 22, they have a long time horizon, so they have a considerable advantage when it comes to compound interest. Invest in the Stock Market While there are numerous ways that a young person can start investing, Johnson recommended that you allocate your funds to a low-cost, diversified equity ETF or mutual fund that mirrors the S&P 500 at an early age. 'For the vast majority of investors, the KISS mantra — keep it simple, stupid — should guide their investment philosophy. Investors simply can't afford to make oversized bets on individual securities,' he said. Johnson admitted that it can be tempting for a young person to purchase the stock of a product they like or a company they work for, but that investing in a broadly diversified basket of securities is a prudent strategy. Johnson pointed out that trying to pick individual winning investments is a loser's game and that the solution is to invest in diversified funds. He also noted that the second advantage of putting it in a low-cost index fund is that you minimize fees. By lowering your costs and spreading out your risk, you can have your funds grow while you focus on building additional savings. Johnson shared the following calculations: 'If our hypothetical 22-year-old investor puts the entire $30,000 into an ETF or mutual fund that mirrors the S&P 500, assuming a 10% annual return (which is 0.4% lower than the historical average), they would accumulate over $1.8 million by age 65,' he said. If this young person starts investing in the stock market today, they'll set themselves up to be a millionaire in their 60s so that they won't have to stress about money in their golden years. Start Investing for Retirement Kaufman acknowledged that saving for retirement at 22 may not feel urgent, but it's the biggest opportunity because this young person could retire much earlier. 'Some great places to start would be to open a Roth IRA and start contributing regularly. Also consider contributing to your employer's 401(k) — especially if there's a match (that's free money),' she added. Make a Financial Plan Kaufman stated that the key is to stay organized and have a plan. 'The goal is simple: give every dollar a job. You've already done the hard part by saving — now it's time to align that money with your goals and put it to work,' she said. Someone with a significant amount of savings at a young age is in a strong position to create financial security. The key is to have a plan for your money so that you stay motivated and focused on the long-term. The plan that you set up will vary based on your personal situation (possible marriage, family plans, travel ambitions and career trajectory) because there's no such thing as a one-size-fits-all solution in money management. More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 10 Genius Things Warren Buffett Says To Do With Your Money 4 Affordable Car Brands You Won't Regret Buying in 2025 This article originally appeared on I'm a 22-Year-Old With Over $30K in My Bank Account: 7 Pieces of Advice From a Financial Advisor Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Insight Molecular Diagnostics Inc (IMDX) Q2 2025 Earnings Call Highlights: Strategic Advances ...
Release Date: August 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Insight Molecular Diagnostics Inc (NASDAQ:IMDX) has completed assay and workflow design improvements, which have been transferred to manufacturing, with the first kits shipped to beta sites in June. The company is on track to submit its FDA product, Ref Assured DX, by the end of the year, maintaining the timeline communicated earlier. IMDX has received positive feedback from transplant centers, with multiple centers validating the new assay. The company has shown a positive predictive value of close to 80% by combining two scores algorithmically, potentially reducing false positives. IMDX is preparing for a meaningful product launch in 2026, with plans to expand into additional solid organ transplant indications, starting with heart transplants. Negative Points The company's Q2 pharma services revenue came in under $500,000, reflecting a challenging revenue environment. Initial second-generation RUO kits do not carry revenue as customers need free samples for validation, delaying revenue generation. Operating expenses remain high due to increased investment in FDA-compliant software development and consulting fees tied to regulatory submission. The company expects a cash burn of about $6 million per quarter until the commercial launch next year, with potential increases in Q3. There is uncertainty regarding the FDA approval timeline, with potential unknowns that could affect the current trial or timeline assumptions. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with IMDX. Q: Can you provide more details on the expected timeline for FDA approval of your product? A: Josh Riggs, CEO: The guidance from the FDA is a 5-month review time. We've budgeted 6 to 7 months, which puts us at the end of Q2 or early Q3 next year. While there are always unknowns, we feel confident in addressing the FDA's concerns. Q: How do you view the recent proposed draft LCD by Palmetto and its potential impact on utilization? A: Josh Riggs, CEO: We support physicians in determining the appropriate testing schedule for their patients. We hope to see movement towards more testing in the future, especially with improved positive predictive value reducing unnecessary biopsies. Q: Have you seen any signs of marginal organs being used more frequently since the iota program went live? A: Josh Riggs, CEO: Feedback from the World Transplant Congress was positive, with encouragement around the program and utilization, although our reach is limited. Q: Can you elaborate on the improvements made to the RUO kits and whether they will be included in the FDA-approved product? A: Dr. Ecky Schutz, Chief Science Officer: We consolidated the assay into a single workflow, simplifying the process and improving precision. This will be included in the FDA-approved product, enhancing market acceptance. Q: How quickly do you expect transplant centers to transition to the Graft Assure DX test after approval? A: Josh Riggs, CEO: We expect a gradual ramp-up, with early converts within health systems. Centers will likely conduct comparative studies before fully transitioning, which could take about a year post-launch. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
